《新英格兰医学杂志》近日正式刊载了针对1型强直性肌营养不良治疗的创新疗法Delpacibart Etedesinan(研发代号Del-Desiran)在MARINA® 1/2期临床试验中所取得的研究数据。该试验旨在评估这一候选药物的安全性与初步疗效,为罕见神经肌肉疾病的治疗领域提供了新的科学依据。
《新英格兰医学杂志》近日正式刊载了针对1型强直性肌营养不良治疗的创新疗法Delpacibart Etedesinan(研发代号Del-Desiran)在MARINA® 1/2期临床试验中所取得的研究数据。该试验旨在评估这一候选药物的安全性与初步疗效,为罕见神经肌肉疾病的治疗领域提供了新的科学依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.